(Q24246085)

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Olsalazine in maintenance of clinical remission in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Optimum dose of olsalazine for maintaining remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

An experiment to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

An oral preparation to release drugs in the human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Cortisone and corticotrophin in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Pentasa in maintenance treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Pentasa in lieu of sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2

Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000544.PUB2